References
- Covián C, Fernández-Fierro A, Retamal-Díaz A, Díaz FE, Vasquez AE, Lay MK, Riedel CA, González PA, Bueno SM, Kalergis AM, et al. BCG- induced cross-protection and development of trained immunity: implication for vaccine design. Front Immunol. 2019;10:2806. doi:10.3389/fimmu.2019.02806.
- Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, Rimmelzwaan GF, Pickkers P, Netea MG. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: A randomized, placebo-controlled pilot study. J Infect Dis. 2015;212:1930–38. doi:10.1093/infdis/jiv332.
- Gursel M, Gursel I. Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic? Allergy. 2020:all.14345. doi:10.1111/all.14345.
- Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395:1545–46. doi:10.1016/S0140-6736(20)31025-4.
- Louis L, Thomas S, Yohann L, Morgan R. Adjustments in the use of intravesical instillations of bacillus calmette-guérin for high-risk non-muscle-invasive bladder cancer during the COVID-19 pandemic. Eur Urol. 2020. doi:10.1016/j.eururo.2020.04.039.
- Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. 2020;323(22):2340–41. doi:10.1001/jama.2020.8189.